Cargando…
Acute and cumulative effects of carboplatin on renal function.
Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247337/ https://www.ncbi.nlm.nih.gov/pubmed/2679841 |
_version_ | 1782150960463740928 |
---|---|
author | Sleijfer, D. T. Smit, E. F. Meijer, S. Mulder, N. H. Postmus, P. E. |
author_facet | Sleijfer, D. T. Smit, E. F. Meijer, S. Mulder, N. H. Postmus, P. E. |
author_sort | Sleijfer, D. T. |
collection | PubMed |
description | Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine 2 mg day 1 and 8 every 4 weeks (max. five cycles) by means of clearance studies with 125I-sodium thalamate and 131I-hippurate to determine GFR and ERPF respectively. Tubular damage was monitored by excretion of tubular enzymes and relative beta 2-microglobulin clearance. During the first course no changes in renal function were seen. After the second course a significant fall in GFR and ERPF started, ultimately leading to a median decrease in GFR of 19.0% (range 6.8-38.7%) and in ERPF of 14% (range 0-38.9%). No increases in the excretion of tubular enzymes or changes in the relative beta 2-microglobulin clearances were seen. We conclude from our data that carboplatin causes considerable loss of renal function. Monitoring renal function in patients treated with multiple courses of carboplatin is warranted. |
format | Text |
id | pubmed-2247337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1989 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22473372009-09-10 Acute and cumulative effects of carboplatin on renal function. Sleijfer, D. T. Smit, E. F. Meijer, S. Mulder, N. H. Postmus, P. E. Br J Cancer Research Article Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine 2 mg day 1 and 8 every 4 weeks (max. five cycles) by means of clearance studies with 125I-sodium thalamate and 131I-hippurate to determine GFR and ERPF respectively. Tubular damage was monitored by excretion of tubular enzymes and relative beta 2-microglobulin clearance. During the first course no changes in renal function were seen. After the second course a significant fall in GFR and ERPF started, ultimately leading to a median decrease in GFR of 19.0% (range 6.8-38.7%) and in ERPF of 14% (range 0-38.9%). No increases in the excretion of tubular enzymes or changes in the relative beta 2-microglobulin clearances were seen. We conclude from our data that carboplatin causes considerable loss of renal function. Monitoring renal function in patients treated with multiple courses of carboplatin is warranted. Nature Publishing Group 1989-07 /pmc/articles/PMC2247337/ /pubmed/2679841 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Sleijfer, D. T. Smit, E. F. Meijer, S. Mulder, N. H. Postmus, P. E. Acute and cumulative effects of carboplatin on renal function. |
title | Acute and cumulative effects of carboplatin on renal function. |
title_full | Acute and cumulative effects of carboplatin on renal function. |
title_fullStr | Acute and cumulative effects of carboplatin on renal function. |
title_full_unstemmed | Acute and cumulative effects of carboplatin on renal function. |
title_short | Acute and cumulative effects of carboplatin on renal function. |
title_sort | acute and cumulative effects of carboplatin on renal function. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247337/ https://www.ncbi.nlm.nih.gov/pubmed/2679841 |
work_keys_str_mv | AT sleijferdt acuteandcumulativeeffectsofcarboplatinonrenalfunction AT smitef acuteandcumulativeeffectsofcarboplatinonrenalfunction AT meijers acuteandcumulativeeffectsofcarboplatinonrenalfunction AT muldernh acuteandcumulativeeffectsofcarboplatinonrenalfunction AT postmuspe acuteandcumulativeeffectsofcarboplatinonrenalfunction |